S30 38. Go RS, Heien HC, Sangaralingham LR, et al: Estimating the Risk of Progression of Monoclonal Gammopathy of Undetermined Significance into Lymphoplasmacytic Malignancies in the United States: Determining Demographic Differences Using a National Dataset. Blood 128:843-843, 2016 39. Kyle RA, Larson DR, Therneau TM, et al: Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 378:241-249, 2018 40. Kyle RA, Greipp PR: Smoldering multiple myeloma. N Engl J Med 302:1347-9, 1980 41. International Myeloma Working G: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749-57, 2003 42. RajkumarV, Dimopoulos M, Palumbo A, et al: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:538-548, 2014. 43. Hillengass J, Fechtner K, Weber MA, et al: Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28:1606-10, 2010 44. Kastritis E, Moulopoulos LA, Terpos E, et al: The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia 28:2402-3, 2014 45. Kastritis E, Terpos E, Moulopoulos L, et al: Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 27:94753, 2013 46. Larsen JT, Kumar SK, Dispenzieri A, et al: Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 27:941-6, 2013 47. Rajkumar SV, Larson D, Kyle RA: Diagnosis of smoldering multiple myeloma. N Engl J Med 365:474-5, 2011 48. Kyle RA, Remstein ED, Therneau TM, et al: Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356:2582-90, 2007 49. Perez-Persona E, Vidriales MB, Mateo G, et al: New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110:2586-92, 2007 50. Dispenzieri A, Kyle RA, Katzmann JA, et al: Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111:785-9, 2008 51. Lakshman A, Rajkumar SV, Buadi FK, et al: Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 8:59, 2018 52. Miguel JS, Mateos M-V, Gonzalez V, et al: Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. Journal of Clinical Oncology 37:8000-8000, 2019 53. Neben K, Jauch A, Hielscher T, et al: Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 31:4325-32, 2013 54. Rajkumar SV, Gupta V, Fonseca R, et al: Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27:1738-44, 2013 55. Chng WJ, Huang GF, Chung TH, et al: Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25:1026-35, 2011 56. Shou Y, Martelli ML, Gabrea A, et al: Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 97:228-33, 2000 57. Dhodapkar MV, Sexton R, Waheed S, et al: Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85, 2014 58. Fernandez de Larrea C, Isola I, Pereira A, et al: Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia 32:14271434, 2018 59. Ravi P, Kumar S, Larsen JT, et al: Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J 6:e454, 2016 60. Wu V, Moshier E, Leng S, et al: Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv 2:1470-1479, 2018 61. Rajkumar SV, Landgren O, Mateos M-V: Smoldering multiple myeloma. Blood 125:3069-3075, 2015 62. Cowan A, Ferrari F et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study Lancet Haematol 2023; 10: e203–12 63. Hillengass J, Usmani S, Rajkumar SV, et al: International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20:e302-e312, 2019 64. Mateos MV, Hernandez MT, Giraldo P et al. Lenalidomide plus dexamethasone for high-risk smoldering myeloma. N Engl J Med 369:438-447, 2013. 65. Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of Lenaliomide verus Observation in Smoldering Multiple Myeloma. J Clin Oncol 38:1126-1137, 2020.
RkJQdWJsaXNoZXIy MTk3NTQxMg==